Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
A Phase II Randomized Study of Cetuximab at Either 500 or 750 mg/m^2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer.
Sponsor: Eli Lilly and Company
Listed as NCT00661427, this PHASE2 trial focuses on Head and Neck and Squamous Cell Cancer and remains completed. Sponsored by Eli Lilly and Company, it has been updated 12 times since 2007, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Nov 2019 [monthly]
Completed PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE2
-
Dec 2017 — Feb 2018 [monthly]
Completed PHASE2
-
Oct 2017 — Dec 2017 [monthly]
Completed PHASE2
-
Feb 2017 — Oct 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Nov 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
- Memorial Sloan Kettering Cancer Center
- National Comprehensive Cancer Network
For direct contact, visit the study record on ClinicalTrials.gov .